Trademark Search in Canada

KITE KONNECT

View On IC.GC.CA

REGISTERED

on 13 Mar 2023

Last Applicant/ Owned by

KITE PHARMA INC.

2400 BroadwaySanta Monica, CA 90404

Serial Number

1954719 filed on 1^st Apr 2019

Registration Number

TMA1170566 registered on 13^th Mar 2023

Registration expiry Date

13^th Mar 2033

Correspondent Address

DLA PIPER (CANADA) LLP

Suite 2700, The Stack1133 Melville StVancouver

BRITISH COLUMBIA

V6E4E5

KITE KONNECT

Trademark usage description

pharmaceutical preparations and biopharmaceuticals for immunotherapy, namely, t cell therapy pharmaceutical preparations for the treatment of cancer; Read More

Classification Information

Class [005]
Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for use in immunotherapies; pharmaceutical preparations for use in T-cell immunotherapy;

Classification kind code

Mark Details

Serial Number

1954719

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 191 on 22^nd Feb 2023	Registration Fee Notice Sent
Submitted for opposition 190 on 22^nd Feb 2023	Registration Pending
Submitted for opposition 42 on 30^th Nov 2022	Advertised
Submitted for opposition 26 on 1^st Nov 2022	Approved
Submitted for opposition 27 on 1^st Nov 2022	Approval Notice Sent
Submitted for opposition 22 on 26^th Oct 2022	Search Recorded
Submitted for opposition 287 on 18^th Aug 2022	Pre-Assessment Letter Sent
Submitted for opposition 31 on 3^rd Apr 2019	Formalized
Submitted for opposition 1 on 2^th Apr 2019	Created
Submitted for opposition 30 on 1^st Apr 2019	Filed

KITE KONNECT

Classification Information

Class [005]Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for use in immunotherapies; pharmaceutical preparations for use in T-cell immunotherapy;

Classification kind code

Mark Details

Serial Number

Mark Type

Legal History

Class [005]
Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for use in immunotherapies; pharmaceutical preparations for use in T-cell immunotherapy;